Rachele Nardella | Meet the Speakers: Med-Tech Expo 2026

Key Takeaways

• ISO 10993‑1:2025 updates reshape biocompatibility assessments
• Early regulatory alignment cuts redesign costs by up to 30%
• Strategic biocompatibility planning shortens market entry timelines
• TÜV SÜD offers consultancy to implement new standards

Pulse Analysis

The 2025 revision of ISO 10993‑1 introduces stricter criteria for evaluating the biological safety of medical devices, shifting the focus from post‑design testing to proactive risk assessment. This change reflects regulators’ desire for more robust data packages that can predict patient outcomes earlier in development. Companies that treat biocompatibility as a mere compliance checkbox risk falling behind competitors who embed safety considerations into the product concept stage.

For med‑tech firms, the new standard presents an opportunity to convert a traditional bottleneck into a strategic lever. By integrating biocompatibility testing into the early design phase, manufacturers can avoid late‑stage redesigns that inflate R&D budgets and delay market entry. Rachele Nardella’s session at Med‑Tech Expo 2026 outlines a business‑aligned safety framework that aligns engineering decisions with regulatory expectations, promising cost reductions of up to 30% and tighter launch schedules. The practical guidance includes roadmap templates, risk‑based prioritization, and real‑world case studies demonstrating measurable ROI.

The broader industry impact extends beyond individual product lines. As regulators worldwide adopt the ISO 10993‑1:2025 language, a unified approach to safety data will streamline global submissions, reducing duplicate testing across regions. Expert partners like TÜV SÜD are positioned to help companies navigate the transition, offering validation services and training that accelerate compliance. Attendees of the Med‑Tech Expo will gain actionable insights to turn regulatory change into a competitive advantage, reinforcing the sector’s commitment to patient safety while protecting bottom‑line performance.